New company just set up to get more than 100 million U.S. dollars in financing gene therapy new enterprises how "fire"

On October 23, Avanti Bio, a Massachusetts-based company, completed a $107 million round of A-round financing and announced the formation of an investment arm of Perceptive Advisors, Bain Capital, RA Capital and Sarepta Therapeutics.
Avanti Bio will focus on developing innovative gene therapies to treat rare diseases and improve patients' lives.
gene therapy currently being developed by Avanti Bio focuses on Friedrich's Ataxia, a rare genetic disorder.
can lead to degeneration of the spinal cord, peripheral nerves and the small brain, as well as damage to muscle coordination (common disorders), motor problems and neurological damage.
patients may also experience other problems such as heart problems, diabetes, or spinal bending.
AvantiBio was co-founded by renowned scholars in gene therapy, Dr. Barry Byrne and Dr. Manuela Corti, and the company's main research products are based on the results of years of basic research in the field of FA diseases and are expanded on that basis.
Avanti Bio has also established strategic partnerships with the University of Florida's Powell Gene Therapy Center and UF Health's MDA Care Center, where it conducts some of the company's research and clinical trials.
"AavantiBio's core mission is to leverage our deep scientific knowledge to serve unseemly patient needs, to think about the company's future prospects, and to have the opportunity to lead this innovative company," Mr. Bo Cumbo, CEO and President of AvantiBio, said in an interview.
with advances in science, clinical and medicine, gene therapy will play an increasingly important role in treating diseases caused by specific genetic mutations.
investment institutions also predict that the gene therapy market is still in its early stages and that there is still a lot of room for growth in the future.
the pharmaceutical health sector has been hotly funded this year, and gene therapy-based start-ups have received a lot of attention from capital, with several start-ups completing rounds of over $100 million in large-scale financings, including Tay Genensha Therapies, Freeline Therapeutics, Poseida Therapeutics, Akouos, Generation Bio, Passage Bio and Beam Therapeutics.
also covers a wide range of disease areas: central nervous system diseases, hearing gene diseases, tumors, ophthalmic diseases, rare diseases, is expected to bring more new treatment options to a wide range of patients.
we also expect more patients to benefit from the advent of more mature products in gene therapy.
: Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics Retrieved October 23, 2020, from